Bioxyne Ltd (ASX: BXN) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Bioxyne Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $26.64 million
P/E Ratio 140.85
Dividend Yield 0.00%
Shares Outstanding 2.05 billion
Earnings per share -0.008
Dividend per share N/A
Year To Date Return 27.27%
Earnings Yield 0.71%
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Bioxyne Ltd (ASX: BXN)
    Latest News

    No posts found.

    BXN ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Bioxyne Ltd

    Bioxyne Ltd is an Australian life science and health products company. The company is engaged in the development, manufacture, and distribution of consumer dietary supplements based on the proprietary probiotic strain of Lactobacillus Fermentum PCC. Some of its products include Breathe life Science, Dr Watson, BLS Clinics, Mirai Solution, CanXChange etc. It operates in three segments: wholesale sales, Plant based and direct sales. The majority of the revenue is generated from Plant based in the United Kingdom, Europe and Japan.

    BXN Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    21 Nov 2024 $0.01 $0.00 0.00% 2,475,400 $0.01 $0.01 $0.01
    20 Nov 2024 $0.01 $0.00 0.00% 500,000 $0.01 $0.01 $0.01
    19 Nov 2024 $0.01 $0.00 0.00% 2,408,695 $0.01 $0.01 $0.01
    18 Nov 2024 $0.01 $0.00 0.00% 3,204,947 $0.01 $0.01 $0.01
    15 Nov 2024 $0.01 $0.00 0.00% 500,000 $0.01 $0.01 $0.01
    14 Nov 2024 $0.01 $0.00 0.00% 59,907 $0.01 $0.01 $0.01
    13 Nov 2024 $0.01 $0.00 0.00% 2,305,642 $0.01 $0.01 $0.01
    12 Nov 2024 $0.01 $0.00 0.00% 52,500 $0.01 $0.01 $0.01
    11 Nov 2024 $0.01 $0.00 0.00% 431,753 $0.01 $0.01 $0.01
    08 Nov 2024 $0.01 $0.00 0.00% 442,776 $0.01 $0.01 $0.01
    07 Nov 2024 $0.01 $0.00 0.00% 527,667 $0.01 $0.01 $0.01
    06 Nov 2024 $0.01 $0.00 0.00% 160,000 $0.01 $0.01 $0.01
    05 Nov 2024 $0.01 $0.00 0.00% 100,000 $0.01 $0.01 $0.01
    01 Nov 2024 $0.01 $0.00 0.00% 3,739,915 $0.01 $0.01 $0.01
    31 Oct 2024 $0.01 $0.00 0.00% 3,102,392 $0.01 $0.01 $0.01
    30 Oct 2024 $0.01 $0.00 0.00% 178,242 $0.01 $0.01 $0.01
    29 Oct 2024 $0.01 $0.00 0.00% 610,523 $0.01 $0.01 $0.01
    28 Oct 2024 $0.01 $0.00 0.00% 342,255 $0.01 $0.01 $0.01
    25 Oct 2024 $0.01 $0.00 0.00% 985,783 $0.01 $0.01 $0.01
    24 Oct 2024 $0.01 $0.00 0.00% 106,276 $0.01 $0.01 $0.01
    23 Oct 2024 $0.01 $0.00 0.00% 1,612,447 $0.01 $0.01 $0.01

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Anthony (Tony) Peng Ho Non-Executive DirectorNon-Executive Chairman Oct 2012
    Mr Ho is an experienced company director having held executive directorships and chief financial officer roles with several ASX listed companies. Tony was executive director of Arthur Yates & Co Limited, retiring from that position in April 2002. His corporate, general management and governance experience includes being chief financial officer/finance director of M.S. McLeod Holdings Limited, Galore Group Limited, the Edward H O'Brien group of companies. Prior to joining commerce, Mr Ho was a partner of Cox Johnston & Co, Chartered Accountants, which has since merged with Ernst & Young.
    Mr Samuel Watson Chief Executive OfficerManaging Director May 2023
    Mr Watson is the founder and CEO of Breathe Life Sciences (BLS). Since establishing BLS and the Dr Watson Brand in 2018, BLS has become a player in the health and wellness industry in Europe, UK and Japan. In 2020, BLS entered the Australian market and has grown rapidly into a market leading manufacturer of novel medicines such as MDMA, Psilocybin, and Cannabis.
    Mr Jason Hine Non-Executive Director May 2023
    Mr Hine was previously the GM Commercial Operations for ECS Botanics Limited, an Australian medicinal cannabis cultivator and hemp food wellness business. The ECS food & wellness business delivers high quality Tasmanian grown/sourced hemp food and wellness products into the Australian grocery sector via the large grocery chains, regional distributors, and a growing bulk supply and B2C channel. Mr Hine has been an executive director of several companies spanning the manufacturing, power distribution, finance, negotiation, consulting and training industries over a 30-year career.
    Mr Guy Adrian Robertson Company Secretary Sep 2016
    -
    Guy Adrian Robertson Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Breathe International Ltd 576,268,527 28.16%
    Ian Edward Owles 132,488,966 6.47%
    Global Cr Holdings Ltd 114,050,086 5.57%
    Kirkman Trading Ltd 82,805,604 4.05%
    Bpmgmt Ltd 79,493,379 3.88%
    Kirkman Trading Ltd i 75,000,000 3.66%
    Nam Hoat Chua 63,574,013 3.11%
    Zonetech Wellness Ltd 57,732,857 2.82%
    Peng Hyang Ng 51,500,000 2.52%
    Paramount Star Investments Limited 36,000,000 1.76%
    Paula Ogilvie 34,778,354 1.70%
    Gavin James Ogilvie 34,778,354 1.70%
    Andrew Alexander Ogilvie 34,778,354 1.70%
    Terrence Stephens Pty Ltd 34,778,354 1.70%
    BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient> 34,223,344 1.67%
    Grace Investments Fzco 30,000,000 1.47%
    Sadamichi Teraguchi 30,000,000 1.47%
    Mr Anthony Peng Ho & Mrs Chui Hoong Ho 24,390,750 1.19%
    Kee Siong Chia 23,050,000 1.13%
    Mr Makram Hanna & Mrs Rita Hanna <Hanna & Co P/L Super A/C> 22,588,594 1.10%
    Chun Chieh Hsu 20,000,000 0.98%
    Taos Pty Ltd <Geilings & Co Pty Super A/C> 18,750,036 0.92%
    Mr Jason John Stephens 18,309,367 0.89%
    Southam Investments 2003 Pty Ltd <Warwickshire Investment A/C> 17,021,550 0.82%

    Profile

    since

    Note